CardioSignal expands to India to offer smartphone-based heart health monitoring
With a large population with over half a billion smartphone users and growing demand for at-home solutions in heart health monitoring, India is the next natural step in CardioSignal’s global expansion.
In December 2021, CardioSignal, a health application for the detection of atrial fibrillation, will be available in India in Google Play and App Store. CardioSignal is a CE-certified class IIa medical device that helps individuals to monitor their heart health at home with nothing more than a smartphone. CardioSignal’s proprietary technology utilizes sensitive motion sensors than can detect heart motion when placed on the chest for one minute.
“Emerging technologies have a great opportunity to bridge a gap in accessibility of care in heart diseases for the individual, as well as provide relief for the healthcare system in targeting treatment to at-risk individuals. The prevalence of cardiovascular diseases is high in India, especially among people who are just 45 years old. Because atrial fibrillation is often asymptomatic, many go undiagnosed, which significantly increases the risk of stroke,” says MD, Chief Medical Officer Tero-Pekka Alastalo.
The prevalence of cardiovascular diseases in India has been estimated to be 54.5 million. One in four deaths in India are now caused by CVDs, with ischemic heart disease and stroke responsible for >80% of this burden. There is a significant unmet need for accessible heart health solutions to enable people to seek medical help in a timely manner to prevent adverse outcomes.
“Digital health is estimated to grow fastest in India. The trend has accelerated after the global COVID-19 pandemic, which increased the need for at-home monitoring. An important part of our market entry is forming meaningful partnerships with healthcare institutions, biopharma and researchers to collaborate on future clinical studies and scientific publications on the potential of emerging technology as a screening tool,” says MD, CEO Juuso Blomster.
Further information:
Juuso Blomster, CEO, juuso.blomster@cardiosignal.com
Tero-Pekka Alastalo, CMO, tpa@cardiosignal.com
Juulia Simonen (Communications) juulia.simonen@cardiosignal.com, tel. +358503059018
About CardioSignal
We develop groundbreaking solutions for the detection of heart diseases. CardioSignal is a mobile application and a certified medical device for the detection of atrial fibrillation. Originally an academic spinoff, the company’s patented technology is built on a decade of research and algorithm development. CardioSignal is a brand and a product by Precordior. www.cardiosignal.com
Sources:
Cardiovascular diseases (WHO): https://www.who.int/india/health-topics/cardiovascular-diseases.
Impending epidemic of cardiovascular diseases among lower socioeconomic groups in India 2021. The Lancet Healthy Longevity.
The changing patterns of cardiovascular diseases and their risk factors in the states of India: the Global Burden of Disease Study 1990–2016. Lancet Glob Health. 2018.
